Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of regorafenib versus trifluridine/tipiracil sequencing in metastatic colorectal cancer
2019-004196-39Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib and trifluridine + tipiracil in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC) and colon adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Feasibility of treatment sequence. Started Jun 2020; status: completed.
02
Drugs
regorafenibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)colon adenocarcinoma
Beyond the preview
Go deeper on 2019-004196-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004196-39.